{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:08:13Z","timestamp":1789690093939,"version":"4.0.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,12]]},"DOI":"10.7759\/cureus.92175","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:15:08Z","timestamp":1757718908000},"source":"Crossref","is-referenced-by-count":2,"title":["Insulin Versus Established GLP-1 Receptor Agonists, DPP-4 Inhibitors, and SGLT-2 Inhibitors for Uncontrolled Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.7759","author":[{"given":"Ammar","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waddah","family":"Abd El-Radi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnakumar","family":"Rajamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Centers for Disease Control and Prevention. National Diabetes Statistics Report. (2023). https.\/\/www.cdc.gov\/diabetes\/php\/data-research\/index.html."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-s064","article-title":"Diagnosis and classification of diabetes mellitus","volume":"35","year":"2012","unstructured":"Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012, 35.S64-71. 10.2337\/dc12-s064","journal-title":"Diabetes Care"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1210\/10.1210\/er.2006-0038","article-title":"beta-cell failure in diabetes and preservation by clinical treatment","volume":"28","author":"Wajchenberg BL","year":"2007","unstructured":"Wajchenberg BL. beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev. 2007, 28:187-218. 10.1210\/10.1210\/er.2006-0038","journal-title":"Endocr Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi SE","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al.. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015, 38:140-9. 10.2337\/dc14-2441","journal-title":"Diabetes Care"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-002-0822-9","article-title":"Hypoglycaemia: the limiting factor in glycemic management of type I and II diabetes","volume":"45","author":"Cryer PE","year":"2002","unstructured":"Cryer PE. Hypoglycaemia: the limiting factor in glycemic management of type I and II diabetes. Diabetologia. 2002, 45:937-48. 10.1007\/s00125-002-0822-9","journal-title":"Diabetologia"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.hjc.2018.04.008","article-title":"Prevalence of diabetes mellitus as well as cardiac and other main comorbidities in a representative sample of the adult Greek population in comparison with the general population","volume":"61","author":"Tentolouris A","year":"2020","unstructured":"Tentolouris A, Eleftheriadou I, Athanasakis K, et al.. Prevalence of diabetes mellitus as well as cardiac and other main comorbidities in a representative sample of the adult Greek population in comparison with the general population. Hellenic J Cardiol. 2020, 61:15-22. 10.1016\/j.hjc.2018.04.008","journal-title":"Hellenic J Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000350","article-title":"Heart disease and stroke statistics-2016 update: a report from the American Heart Association","volume":"133","author":"Mozaffarian D","year":"2016","unstructured":"Mozaffarian D, Benjamin EJ, Go AS, et al.. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016, 133:e38-360. 10.1161\/CIR.0000000000000350","journal-title":"Circulation"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1318","article-title":"A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study","volume":"34","author":"Colayco DC","year":"2011","unstructured":"Colayco DC, Niu F, McCombs JS, Cheetham TC. A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study. Diabetes Care. 2011, 34:77-83. 10.2337\/dc10-1318","journal-title":"Diabetes Care"},{"key":"ref9","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998, 352:837-53.","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2174\/0929867324666170530075533","article-title":"Update on cardiovascular effects of older and newer anti-diabetic medications","volume":"25","author":"Eleftheriadou I","year":"2018","unstructured":"Eleftheriadou I, Grigoropoulou P, Liberopoulos E, Liatis S, Kokkinos A, Tentolouris N. Update on cardiovascular effects of older and newer anti-diabetic medications. Curr Med Chem. 2018, 25:1549-66. 10.2174\/0929867324666170530075533","journal-title":"Curr Med Chem"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman RR","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008, 359:1577-89. 10.1056\/NEJMoa0806470","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019","volume":"42","author":"American Diabetes Association","year":"2019","unstructured":"American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. Diabetes Care. 2019, 42:S90-102. 10.2337\/dc19-S009","journal-title":"Diabetes Care"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker DJ","year":"2006","unstructured":"Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006, 368:1696-705. 10.1016\/S0140-6736(06)69705-5","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(14)70174-3","article-title":"Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) vs its components alone in patients with type 2 diabetes (DUAL I)","volume":"2","author":"Gough SC","year":"2014","unstructured":"Gough SC, Bode B, Woo V, et al.. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) vs its components alone in patients with type 2 diabetes (DUAL I). Lancet Diabetes Endocrinol. 2014, 2:885-93.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1R041","article-title":"Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis","volume":"46","author":"Park H","year":"2012","unstructured":"Park H, Park C, Kim Y, Rascati KL. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. Ann Pharmacother. 2012, 46:1453-69. 10.1345\/aph.1R041","journal-title":"Ann Pharmacother"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-018-1206-z","article-title":"The roots of SGLT inhibition: Laurent-Guillaume de Koninck, Jean Servais Stas and Freiherr Josef von Mering","volume":"56","author":"J\u00f6rgens V","year":"2019","unstructured":"J\u00f6rgens V. The roots of SGLT inhibition: Laurent-Guillaume de Koninck, Jean Servais Stas and Freiherr Josef von Mering. Acta Diabetol. 2019, 56:29-31. 10.1007\/s00592-018-1206-z","journal-title":"Acta Diabetol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-0627","article-title":"Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes","volume":"30","author":"Goldstein BJ","year":"2007","unstructured":"Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007, 30:1979-87. 10.2337\/dc07-0627","journal-title":"Diabetes Care"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2012.02911.x","article-title":"Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial","volume":"66","author":"Henry RR","year":"2012","unstructured":"Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012, 66:446-56. 10.1111\/j.1742-1241.2012.02911.x","journal-title":"Int J Clin Pract"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12540","article-title":"Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and\/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study","volume":"17","author":"Araki E","year":"2015","unstructured":"Araki E, Inagaki N, Tanizawa Y, Oura T, Takeuchi M, Imaoka T. Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and\/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study. Diabetes Obes Metab. 2015, 17:994-1002. 10.1111\/dom.12540","journal-title":"Diabetes Obes Metab"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70029-4","article-title":"Exenatide once weekly vs insulin glargine for type 2 diabetes (DURATION-3, 3-year results)","volume":"2","author":"Diamant M","year":"2014","unstructured":"Diamant M, van Gaal L, Guerci B, et al.. Exenatide once weekly vs insulin glargine for type 2 diabetes (DURATION-3, 3-year results). Lancet Diabetes Endocrinol. 2014, 2:464-73. 10.1016\/S2213-8587(14)70029-4","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12200","article-title":"Glucagon-like peptide 1 receptor agonist therapy is more efficacious than insulin glargine for poorly controlled type 2 diabetes: A systematic review and meta-analysis","volume":"7","author":"Liu FP","year":"2015","unstructured":"Liu FP, Dong JJ, Yang Q, Xue XZ, Ren ZF, Gan YZ, Liao L. Glucagon-like peptide 1 receptor agonist therapy is more efficacious than insulin glargine for poorly controlled type 2 diabetes: A systematic review and meta-analysis. J Diabetes. 2015, 7:322-8. 10.1111\/1753-0407.12200","journal-title":"J Diabetes"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14153","article-title":"Combination therapy with pioglitazone\/exenatide improves beta-cell function and produces superior glycaemic control compared with basal\/bolus insulin in poorly controlled type 2 diabetes: a 3-year follow-up of the Qatar study","volume":"22","author":"Abdul-Ghani M","year":"2020","unstructured":"Abdul-Ghani M, Migahid O, Megahed A, DeFronzo RA, Al-Ozairi E, Jayyousi A. Combination therapy with pioglitazone\/exenatide improves beta-cell function and produces superior glycaemic control compared with basal\/bolus insulin in poorly controlled type 2 diabetes: a 3-year follow-up of the Qatar study. Diabetes Obes Metab. 2020, 22:2287-94. 10.1111\/dom.14153","journal-title":"Diabetes Obes Metab"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025","volume":"48","author":"American Diabetes Association","year":"2025","unstructured":"American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025. Diabetes Care. 2025, 48:S181-206. 10.2337\/dc25-S009","journal-title":"Diabetes Care"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"65","author":"Davies MJ","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, et al.. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022, 65:1925-66. 10.1007\/s00125-022-05787-2","journal-title":"Diabetologia"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30085-2","article-title":"Semaglutide once weekly vs insulin glargine (SUSTAIN-4)","volume":"5","author":"Aroda VR","year":"2017","unstructured":"Aroda VR, Bain SC, Cariou B, et al.. Semaglutide once weekly vs insulin glargine (SUSTAIN-4). Lancet Diabetes Endocrinol. 2017, 5:355-66. 10.1016\/S2213-8587(17)30085-2","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60439-5","article-title":"Insulin glargine vs sitagliptin (EASIE trial)","volume":"379","author":"Aschner P","year":"2012","unstructured":"Aschner P, Chan J, Owens DR, et al.. Insulin glargine vs sitagliptin (EASIE trial). Lancet. 2012, 379:2262-9. 10.1016\/S0140-6736(12)60439-5","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12406","article-title":"Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes","volume":"17","author":"D'Alessio D","year":"2015","unstructured":"D'Alessio D, H\u00e4ring HU, Charbonnel B, et al.. Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes. Diabetes Obes Metab. 2015, 17:170-8. 10.1111\/dom.12406","journal-title":"Diabetes Obes Metab"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-1333","article-title":"Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas","volume":"36","author":"Davies M","year":"2013","unstructured":"Davies M, Heller S, Sreenan S, Sapin H, Adetunji O, Tahbaz A, Vora J. Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas. Diabetes Care. 2013, 36:1368-76. 10.2337\/dc12-1333","journal-title":"Diabetes Care"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2013.09.2704","article-title":"Exenatide once weekly versus daily basal insulin as add-on treatment to metformin with or without a sulfonylurea: a retrospective pooled analysis in patients with poor glycemic control","volume":"125","author":"Grimm M","year":"2013","unstructured":"Grimm M, Li Y, Brunell SC, Blase E. Exenatide once weekly versus daily basal insulin as add-on treatment to metformin with or without a sulfonylurea: a retrospective pooled analysis in patients with poor glycemic control. Postgrad Med. 2013, 125:101-8. 10.3810\/pgm.2013.09.2704","journal-title":"Postgrad Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2012.07.007","article-title":"Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study","volume":"34","author":"Inagaki N","year":"2012","unstructured":"Inagaki N, Atsumi Y, Oura T, Saito H, Imaoka T. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study. Clin Ther. 2012, 34:1892-908.e1. 10.1016\/j.clinthera.2012.07.007","journal-title":"Clin Ther"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002961","article-title":"Sitagliptin\/metformin versus insulin glargine combined with metformin in obese subjects with newly diagnosed type 2 diabetes","volume":"95","author":"Ji M","year":"2016","unstructured":"Ji M, Xia L, Cao J, Zou D. Sitagliptin\/metformin versus insulin glargine combined with metformin in obese subjects with newly diagnosed type 2 diabetes. Medicine (Baltimore). 2016, 95:e2961. 10.1097\/MD.0000000000002961","journal-title":"Medicine (Baltimore)"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12003","article-title":"Taspoglutide, a once-weekly glucagon-like peptide 1 analogue, vs. insulin glargine titrated to target in patients with type 2 diabetes: an open-label randomized trial","volume":"30","author":"Nauck M","year":"2013","unstructured":"Nauck M, Horton E, Andjelkovic M, Ampudia-Blasco FJ, Parusel CT, Boldrin M, Balena R. Taspoglutide, a once-weekly glucagon-like peptide 1 analogue, vs. insulin glargine titrated to target in patients with type 2 diabetes: an open-label randomized trial. Diabet Med. 2013, 30:109-13. 10.1111\/dme.12003","journal-title":"Diabet Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12115","article-title":"Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents","volume":"15","author":"Philis-Tsimikas A","year":"2013","unstructured":"Philis-Tsimikas A, Del Prato S, Satman I, et al.. Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents. Diabetes Obes Metab. 2013, 15:760-6. 10.1111\/dom.12115","journal-title":"Diabetes Obes Metab"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1988","article-title":"Dapagliflozin plus saxagliptin add-on therapy compared with insulin in patients with type 2 diabetes poorly controlled by metformin with or without sulfonylurea therapy: a randomized clinical trial","volume":"42","author":"Vilsb\u00f8ll T","year":"2019","unstructured":"Vilsb\u00f8ll T, Ekholm E, Johnsson E, Dronamraju N, Jabbour S, Lind M. Dapagliflozin plus saxagliptin add-on therapy compared with insulin in patients with type 2 diabetes poorly controlled by metformin with or without sulfonylurea therapy: a randomized clinical trial. Diabetes Care. 2019, 42:1464-72. 10.2337\/dc18-1988","journal-title":"Diabetes Care"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13506","article-title":"Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and\/or a sulphonylurea: A 52-week open-label, randomized phase III trial","volume":"21","author":"Wang W","year":"2019","unstructured":"Wang W, Nev\u00e1rez L, Filippova E, et al.. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and\/or a sulphonylurea: A 52-week open-label, randomized phase III trial. Diabetes Obes Metab. 2019, 21:234-43. 10.1111\/dom.13506","journal-title":"Diabetes Obes Metab"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins JP","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al.. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011, 343:d5928. 10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12804","article-title":"A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients","volume":"19","author":"Abd El Aziz MS","year":"2017","unstructured":"Abd El Aziz MS, Kahle M, Meier JJ, Nauck MA. A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. Diabetes Obes Metab. 2017, 19:216-27. 10.1111\/dom.12804","journal-title":"Diabetes Obes Metab"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12805","article-title":"Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"19","author":"Singh S","year":"2017","unstructured":"Singh S, Wright EE Jr, Kwan AY, et al.. Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab. 2017, 19:228-38. 10.1111\/dom.12805","journal-title":"Diabetes Obes Metab"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005752","article-title":"Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis","volume":"4","author":"Tricco AC","year":"2014","unstructured":"Tricco AC, Antony J, Khan PA, et al.. Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis. BMJ Open. 2014, 4:e005752. 10.1136\/bmjopen-2014-005752","journal-title":"BMJ Open"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S009","article-title":"Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2021","volume":"44","author":"American Diabetes Association","year":"2021","unstructured":"American Diabetes Association. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2021. Diabetes Care. 2021, 44:S111-24. 10.2337\/dc21-S009","journal-title":"Diabetes Care"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/408386-insulin-versus-established-glp-1-receptor-agonists-dpp-4-inhibitors-and-sglt-2-inhibitors-for-uncontrolled-type-2-diabetes-mellitus-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:15:16Z","timestamp":1757718916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/408386-insulin-versus-established-glp-1-receptor-agonists-dpp-4-inhibitors-and-sglt-2-inhibitors-for-uncontrolled-type-2-diabetes-mellitus-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":40,"URL":"https:\/\/doi.org\/10.7759\/cureus.92175","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,12]]}}}